Section III. Biocompatibility

Nephrology Dialysis Transplantation

Volumn 17, Issue SUPPL. 7, 2002, Pages 32-44

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN;

AMYLOIDOSIS; ARTIFICIAL KIDNEY; ATHEROGENESIS; BIOCHEMISTRY; BIOCOMPATIBILITY; COMPLEMENT ACTIVATION; CONTROLLED STUDY; HEMODIALYSIS; HEMODYNAMICS; HUMAN; IMMUNE RESPONSE; INFECTION SENSITIVITY; KIDNEY FUNCTION; LEUKOCYTE ACTIVATION; LUNG FUNCTION; MORBIDITY; MORTALITY; NERVE FUNCTION; NUTRITIONAL STATUS; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SHEAR STRESS; UREMIA;

BIOCOMPATIBLE MATERIALS; HUMANS; MEMBRANES, ARTIFICIAL; RENAL DIALYSIS;

EID: 0036041448     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (260)

1. Increased expression of an adhesion-promoting surface glycoprotein in the granulocytopenia of hemodialysis
2. Compartmental distribution of complement activation products in artificial kidneys
3. Granulocyte activation and adhesion molecules during hemodialysis with cuprophane and a high-flux biocompatible membrane
4. Pulmonary vascular leukostasis resulting from complement activation by dialyzer cellophane membranes
5. Establishing the relationship between complement activation and stimulation of phagocyte oxidative metabolism in hemodialyzed patients: A randomized prospective study
6. Allergy to ethylene oxide in chronic hemodialysis patients
7. Studies of biocompatibility of different dialyzer membranes: Role of complement system, intracellular calcium and inositol-triphosphate
8. In vivo induction of interieukin-1 during hemodialysis
9. Biocompatibility of dialysis membranes: Effects of chronic complement activation
10. Induction of cytokines by dialysis membranes in normal whole blood: A new in vitro assay for evaluating membrane biocompatibility
11. Soluble complement receptor 1 inhibits both complement and granulocyte activation during ex vivo hemodialysis
12. Synthetically modified cellulose: An alternative to synthetic membranes for use in haemodialysis?
13. Acute-phase proteins during hemodialysis: Correlations with serum-1β levels and different dialysis membranes
14. Polymorphonuclear leukocyte function during hemodialysis: Relationship to complement activation
15. Rapid activation of the complement system by cuprophane depends on complement component C4
16. Improved biocompatibility by modified cellulosic membranes: The case of hemophan
17. Biocompatibility of dialysis membranes: A comparative study
18. Role of protein adsorption on haemodialysis-induced complement activation and neutrophil defects
19. Novel C5-dependent mechanism of neutrophil stimulation by bioincompatible dialyzer membranes
20. Plasma levels of bactericidal/permeability-increasing protein (BPI) and lipopolysaccharide-binding protein (LBP) during hemodialysis
21. Mobilization of an intracellular glycoprotein (Mac-1) on monocytes during hemodialysis
22. Adhesion molecules and leukocyte common antigen on monocytes and granulocytes during hemodialysis
23. Evaluation of phagocytic cell function in an ex vivo model of hemodialysis
24. Assembly of terminal SC5b-9 complement complexes: A new index of blood-membrane interaction
25. Fluid phase generation of terminal complement complex as a novel index of bioincompatibility
26. Flow-cytometric study of granulocyte activation during hemodialysis with different membranes
27. Monocyte phenotype and interleukin-1 production in patients undergoing haemodialysis
28. Reactive oxygen species production by monocytes and polymorphonuclear leukocytes during dialysis
29. Intradialytic granulocyte reactive oxygen species production: A prospective, crossover trial
30. Hemodialysis membrane-induced activation of phagocyte oxidative metabolism detected in vivo and in vitro within micro amounts of whole blood
31. Nitric oxide release in the peripheral blood during hemodialysis
32. Leukocyte CD14 and CD45 expression during hemodialysis: Polysulfone versus cuprophane
33. Effect of uremia and hemodialysis on soluble L-selectin and leukocyte surface CD11b and L-selectin
34. Modulation of granulocyte LAM-1 and MAC-1 during dialysis - A prospective, randomized controlled trial
35. Cuprophane haemodialysis induces upregulation of LPS receptor (CD14) on monocytes: Role of complement activation
36. Cell aggregation and apoptosis induced by hemodialysis membranes
37. Complement activation and neutrophil aggregation changes during haemodialysis
38. Second messenger formation altered by different dialysis membranes in human leukocytes
39. Lymphocyte subsets in dialyser eluates: A new parameter of bioincompatibility?
40. Plasma interleukin-1 activity during hemodialysis: The influence of dialysis membranes
41. Role of different dialysis membranes in the release of interleukin-6-soluble receptor in uremic patients
42. Cuprophane but not synthetic membrane induces increases in serum tumor necrosis factor-alpha levels during hemodialysis
43. Induction of tumour necrosis factor-alpha during haemodialysis. Influence of the membrane type
44. Normal T lymphocyte function in patients with end-stage renal disease hemodialyzed with 'high-flux' polysulfone membranes
45. Effects of hemodialysis on activation of lymphocytes: Analysis by an in vitro dialysis model
46. The effect of membrane characteristics on tumour necrosis factor kinetics during haemodialysis
47. Interleukin-6 may mediate malnutrition in chronic hemodialysis patients
48. Cytokine production during hemodialysis: Effects of dialytic membrane and complement activation
49. Studies on the ability of hemodialysis membranes to induce, bind, and clear human interleukin-1
50. Interieukin-6, interleukin-8 and monocyte chemotactic peptide-1 gene expression and protein synthesis are independently modulated by hemodialysis membranes
51. Transcription, not synthesis, of interleukin-1 and tumor necrosis factor by complement
52. Gene expression of interleukin-1 during hemodialysis
53. Hemodialysis with cuprophane membrane modulates interleukin-2 receptor expression
54. Hemodialysis-related lymphomononuclear release of interleukin-12 in patients with end-stage renal disease
55. Serum and intracellular detection of cytokines in patients undergoing chronic hemodialysis
56. Effects of dialyser and dialysate on the acute phase reaction in clinical bicarbonate dialysis
57. 2 integrins are required for neutrophil degranulation induced by hemodialysis membranes
58. Plasma levels of granulocyte elastase during hemodialysis: Effects of different dialyzer membranes
59. Endothelin and platelet activating factor. Possible indices for biocompatibility of hemodialysis
60. Platelet-activating factor production during hemodialysis: Effect of BN 52021
61. 4 generation
62. Cellular proliferation and second messenger formation altered by dialysis membranes
63. Generation of leukotriene B4 by hemodialyzer membranes: A novel index of biocompatibility
64. Evaluation of monocyte chemotactic responsiveness in uraemic patients undergoing haemodialysis with different dialytic membranes
65. Effect of uremia and dialysis modality on mononuclear cell apoptosis
66. Platelet activation on hemodialysis: Influence of dialysis membranes
67. Platelet-leukocyte aggregates during hemodialysis: Effect of membrane type
68. Antigen phenotype and cytotoxic activity of natural killer cells in hemodialysis patients
69. Natural killer-cell function in hemodialysis patients: Effect of the dialysis membrane
70. Production and kinetics of interleukin-1 in hemodialysis
71. Cytokine profiles during clinical high-flux dialysis: No evidence for cytokine generation by circulating monocytes
72. Differential effect of hemodialysis membranes on human lymphocyte natural killer function
73. Evolution of serum pre-albumin following hemodialysis: Effect of different dialysis membranes
74. Clinical implications of hemodialysis membrane biocompatibility
75. Leukotriene release from neutrophils of patients on hemodialysis with cellulose membranes
76. Haemodialysis membranes modulate chronically the production of TNF α, IL1β and IL6
77. Behaviour of white blood cells and the complement system
78. Preserved antioxidative defense of lipoproteins in renal failure and during hemodialysis
79. Influence of dialysis with polyamide vs haemophan haemodialysers on monokines and complement activation during a 4-month long-term study
80. Adsorption of unactivated complement proteins by hemodialysis membranes
81. Adsorption of complement factor D by polyacrylonitrile dialysis membranes
82. Activation of complement by hemodialysis membranes: Polyacrylonitrile binds more C3a than cuprophan
83. Particles from dialysis tubing stimulate interleukin-1 secretion by macrophages
84. Biocompatibility differences with respect to dialyzer sterilization method
85. Increased amounts of C3a and the terminal complement complex at high dialysis blood-flow: The relation with dialysis efficacy
86. Effect of the hemodialysis membrane on the inflammatory reaction in vivo
87. C-reactive protein (CRP) as a marker of hemodialysis biocompatibility
88. Effect of biocompatibility of hemodialysis membranes on serum albumin levels
89. C-Reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients
90. Association of morbidity with markers of nutrition and inflammation in chronic hemodialysis patients: A prospective study
91. C-reactive protein as an outcome predictor for maintenance hemodialysis patients
92. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients
93. Inflammation nutritional state and outcome in end stage renal disease
94. Biocompatibility and risk of infection in haemodialysis patients
95. Functional changes of monocytes due to dialysis membranes
96. Impaired leucocyte rolling, adhesion and transendothelial migration following cuprophane hemodialysis
97. Phagocytosis in uremic and hemodialysis patients: A prospective and cross sectional study
98. Infectious morbidity and defects of phagocytic function in end-stage renal disease: A review
99. Depressed phagocytosis in hemodialyzed patients: In vivo and in vitro mechanisms
100. The effects of the dialysis membrane on cytokine release
101. Removal of interleukin-1 beta and tumor necrosis factor from human plasma by in vitro dialysis with polyacrylonitrile membranes
102. Protein adsorption by artificial membrane materials under filtration conditions
103. Cytokine filtration and adsorption during pre- and post-dilution hemofiltration in four different membranes
104. 2 microglobulin in hemodialysis patients: Assessment using total body counting
105. Biocompatibility of hemodialysis membranes
106. 2-microglobulin kinetics: In vivo and in vitro studies
107. Adsorption of complement, cytokines, and proteins by different dialysis membrane materials: Evaluation by confocal laser scanning fluorescence microscopy
108. Proteins adsorbed on hemodialysis membranes modulate neutrophil activation
109. Protein-membrane interactions during hemodialysis. Effects on solute transport
110. Permeability and secondary membrane formation of a high flux polysulfone hemofilter
111. Hemodialysis membrane biocompatibility: The case of erythropoietin
112. The effects of a polyacrylonitrile membrane and a membrane made of regenerated cellulose on the plasma concentrations of erythropoietin during hemodialysis
113. Absence of lung reactions after complement depletion during dialysis: An experimental study in pigs
114. A demonstration of neutrophil accumulation in the pulmonary vasculature during haemodialysis
115. Cardiopulmonary effects of cuprophane-activated plasma in swine
116. Hypoxemia during hemodialysis: Effects of different membranes and dialysate compositions
117. Cuprophan reuse and intradialytic changes of lung diffusion capacity and blood gasses
118. Dissociation between complement activation, integrin expression and neutropenia during hemodialysis
119. Role of intrapulmonary release of eicosanoids and superoxide anion as mediators of pulmonary dysfunction and endothelial injury in sheep with intermittent complement activation
120. Effect of the membrane biocompatibility on nutritional parameters in chronic hemodialysis patients
121. Effect of in vivo contact between blood and dialysis membranes on protein catabolism in humans
122. Protein catabolism in maintenance haemodialysis: The influence of the dialysis membrane
123. Protein catabolism in sham-hemodialysis: The effect of different membranes
124. Malnutrition in hemodialysis patients
125. Amino acid and albumin losses during hemodialysis
126. Nutrition in end-stage disease
127. PCR, Kt/V and membrane
128. The effect of hemodialysis on protein metabolism. A leucine kinetic study
129. Effects of different membranes and dialysis technologies on patient treatment tolerance and nutritional parameters
130. Structure of dialysis membranes and long-term clinical outcome
131. Nitrogen balance during intermittent dialysis therapy of uremia
132. Relationship of dialysis membrane and cause-specific mortality
133. A multivariate analysis of mortality and hospital admissions with high-flux dialysis
134. Switch from conventional to high-flux membrane reduces the risk of carpal tunnel syndrome and mortality of hemodialysis patients
135. EPIBACDIAL: A multicenter prospective study of risk factors for bacteremia in chronic hemodialysis patients
136. Reassessing the cardiac risk profile in chronic hemodialysis patients: A hypothesis on the role of oxidant stress and other non-traditional cardiac risk factors
137. Endothelium: The next frontier in biocompatibility
138. Advanced oxidation protein products as a novel marker of oxidative stress in uremia
139. Autoantibodies against oxidatively modified LDL in uremic patients undergoing dialysis
140. Enhanced LDL oxidation in uremic patients: An additional mechanism for accelerated atherosclerosis?
141. Sensitive detection of oxidatively modified low density lipoprotein using a monoclonal antibody
142. Detection of oxidants in uremic plasma by electron spin resonance spectroscopy
143. Alteration in plasma antioxidant capacities in chronic renal failure and hemodialysis patients: A possible explanation for the increased cardiovascular risk in these patients
144. Increased intracellular reactive oxygen species in patients with end-stage renal failure: Effect of hemodialysis
145. Effect of vitamin E-bonded membrane on the 8-hydroxy 2′-deoxyguanosine level in leukocyte DNA of hemodialysis patients
146. Influence of different hemodialysis membranes on red blood cell susceptibility to oxidative stress
147. Effect of hemodialysis on lipid peroxidation and antioxidant system in patients with chronic renal failure
148. Oxidative stress in haemodialysis
149. Lipid peroxidation on dialysis membranes
150. Enhancement of granulocyte-endothelial cell adherence and granulocyte-induced cytotoxicity by platelet release products
151. Dialysis-induced serum factors inhibit adherence of monocytes and granulocytes to adult human endothelial cells
152. In vivo visualization of hemodialysis-induced alterations in leukocyte-endothelial interactions
153. Bioreactivity and biocompatibility of a vitamin E-modified multi-layer hemodialysis filter
154. Hemodialysis impairs endothelial function via oxidative stress: Effects of vitamin E-coated dialyzer
155. Vitamin E-bonded cellulose membrane and hemodialysis bioincompatibility: Absence of an acute benefit on expression of leukocyte surface molecules
156. High-flux dialysis membranes improve lipid profile in chronic hemodialysis patients
157. High flux dialysis membranes improve plasma lipoprotein profiles in patients with end-stage renal disease
158. Improved lipid profiles in patients undergoing high-flux hemodialysis
159. Effect of dialysis membranes on lipoprotein profile of serum in haemodialysed patients
160. Randomized trial of high-flux vs low-flux haemodialysis: Effects on homocysteine and lipids
161. Biocompatible membranes preserve residual renal function in patients undergoing regular hemodialysis
162. Improved preservation of residual renal function in chronic hemodialysis patients using polysulfone dialyzers
163. The effect of dialyzer membrane and etiology of kidney disease on the preservation of residual renal function in chronic hemodialysis patients
164. The effect of membrane biocompatibility on plasma beta 2-microglobulin levels in chronic hemodialysis patients
165. Effect of hemodialysis and hemodiafiltration on uremic neuropathy
166. Hemodialysis with cuprophane or poly-sulfone: Effects on uremic polyneuropathy
167. 2-microglobulin amyloid
168. Fatal cardiac beta 2-microglobulin amyloidosis in patients on long-term hemodialysis
169. Dialysis-associated arthropathy: A multicentre survey of 171 patients receiving haemodialysis for over 10 years
170. Comparison of mortality in ESRD patients on convective and diffusive extracorporeal treatments
171. Amyloid, advanced glycation end products, and dialysis related arthropathy
172. Long term effect of renal transplantation on dialysis-related amyloid deposits and symptomatology
173. Effect of dialysis membrane and patient's age on signs of dialysis-related amyloidosis
174. 2-microglobulin amyloidosis: Past and future
175. 2-microglobulin-associated amyloid
176. Histological prevalence of β2-microglobulin amyloidosis in hemodialysis: A prospective post-mortem study
177. Beta 2-microglobulin: A new form of amyloid protein associated with chronic hemodialysis
178. Hemodialysis-associated amyloidosis and beta-2 microglobulin. Clinical and immunohistochemical study
179. 2-microglobulin production and cellular expansion
180. 2-Microglobulin and low-flux synthetic dialyzers
181. Intradialytic body weight changes and dialyzer pore size as main contributing factors to the evolution of beta-2-microglobulin in dialysis
182. 2-microglobulin concentrations to normal in haemodialysis patients
183. High-flux hemodialysis postpones clinical manifestation of dialysis-related amyloidosis
184. Fitness of biocompatible high-flux hemodiafiltration for dialysis-related amyloidosis
185. Clinical manifestations of AB-amyloidosis: Effects of biocompatibility and flux
186. Carpal tunnel syndrome and type of dialysis membrane
187. 2-microglobulin removal by different hemodialysis membranes: A six-year follow-up
188. Radiolucent bone cysts and the type of dialysis membrane used in patients undergoing long-term hemodialysis
189. Clinical experience and model analysis on beta-2-microglobulin kinetics in high-flux hemodialysis
190. 2-Microglobulin associated amyloidosis: A vanishing complication of long-term hemodialysis?
191. Interaction between β2-microglobulin and advanced glycation end products in the development of dialysis related-amyloidosis
192. 2-microglobulin modified with advanced glycation end products is a major component of hemodialysis-associated amyloidosis
193. Glycation of human beta 3-microglobulin in patients with hemodialysis-associated amyloidosis: Identification of the glycated sites
194. 2-microglobulin modified with advanced glycation end products in the pathogenesis of hemodialysis-associated amyloidosis
195. 2-microglobulin modified with advanced glycation end products
196. Identification of pentosidine as a native structure for advanced glycation end products in β2-microglobulin-containing amyloid fibrils in patients with dialysis-related amyloidosis
197. N epsilon-(carboxymethyl)lysine in blood from maintenance hemodialysis patients may contribute to dialysis-related amyloidosis
198. Immunohistochemical detection of advanced glycation end products in dialysis-related amyloidosis
199. 2-microglobulin is modified with Nε-(carboxymethyl)lysine in dialysis-related amyloidosis
200. 2-m with advanced glycation end products as observed in dialysis-related amyloidosis by 3-DG accumulating in uremic serum
201. 2-microglobulin is modified with imidazolone, a novel advanced glycation end product, in dialysis-related amyloidosis
202. The advanced glycation endproduct, pentosidine, in the carpal ligament in patients with carpal tunnel syndrome undergoing hemodialysis: Comparison with idiopathic carpal tunnel syndrome
203. Alterations in nonenzymatic biochemistry in uremia: Origin and significance of 'carbonyl stress' in long-term uremic complications
204. 2-Microglobulin modified with advanced glycation end products induces interleukin-6 from human macrophages. Role in the pathogenesis of hemodialysis-associated amyloidosis
205. 2 microglobulin with human mononuclear phagocytes via an oxidant-sensitive pathway
206. Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure
207. Impaired lysosomal processing of beta2-microglobulin by infiltrating macrophages in dialysis amyloidosis
208. Influence of hemodialysis membrane type on pentosidine plasma level, a marker of 'carbonyl stress'
209. Beta 2 microglobulin isoforms in healthy individuals and in amyloid deposits
210. 2-Microglobulin as the amyloidogenic protein in dialysis-amyloidosis
211. Patient survival on PAN/AN69 membrane hemodialysis: A ten-year analysis
212. Clinical impact of biocompatible dialysis membranes on patient morbidity and mortality: An appraisal of the evidence
213. Effect of the dialysis membrane on mortality of chronic hemodialysis patients
214. Influence of high-flux biocompatible membrane on carpal tunnel syndrome and mortality
215. Effect of dialysis membranes and middle molecule removal on chronic hemodialysis patient survival
216. Mortality risk by hemodialyzer reuse practice and dialyzer membrane characteristics: Results from the USRDS Dialysis Morbidity and Mortality Study
217. Trends in treatment and survival for hemodialysis patients in the United States
218. Silicone-induced splenomegaly. Treatment of pancytopenia by splenectomy in a patient on hemodialysis
219. Plastic filing from dialysis tubing induces prostanoid release from macrophages
220. Particle spallation and plasticiser (DEHP) release from extracorporeal circuit tubing materials
221. Spallation and plasticizer release from hemodialysis blood tubing: A cause of concern?
222. Spallation and migration of silicone from blood-pump tubing in patients on hemodialysis
223. Reduction of silicone particle release during haemodialysis
224. Anaphylactoid reactions in dialysis patients: Role of ethylene oxide
225. The fate of leached di-(2-ethylhexyl)-phthalate (DEHP) in patients on chronic haemodialysis
226. Leachability of a new plasticizer tri-(2-ethylhexyl)-trimellitate from haemodialysis tubing
227. Delivery of di-2-ethylhexyl phthalate to patients during hemodialysis
228. Bis(2-ethylhexyl)phthalate concentrations in the serum of hemodialysis patients
229. Allergy in long-term hemodialysis. II. Allergic and atopic patterns of a population of patients undergoing long-term hemodialysis
230. Hypersensitivity reactions during haemodialysis: Role of complement fragments and ethylene oxide antibodies
231. Reactions during hemodialysis caused by allergy to ethylene oxide gas sterilization
232. Ethylene oxide sensitivity in hemodialysis patients
233. Association of ethylene-oxide-induced IgE antibodies with symptoms in dialysis patients
234. Steam sterilization: A suitable alternative?
235. Effect of first and subsequent use of hemodialyzers on patient well being. Analysis of the incidence of symptoms and events and description of a syndrome associated with new dialyzer use
236. Ethylene-oxide and steam-sterilised polysulfone membrane in dialysis patients with eosinophilia
237. A survey of hypersensitivity reactions in hemodialysis
238. Plate, coil, and hollow-fiber cuprammonium cellulose dialyzers: Discrepancy between incidence of anaphylactic reactions and degree of complement activation
239. Antibody responses to hemodialysis-related antigens in chronic hemodialysis patients
240. Allergy to dialysis materials
241. Chemically induced polycystic kidney disease
242. Exposure of patients to phthalates from polyvinyl chloride tubes and bags during dialysis
243. Is there a need for plasticizer-free biomaterials in dialysis therapy?
244. Alteration of hepatic phospholipids in rats and mice by feeding di-(2-ethylhexyl)adipate and di-(2-ethylhexyl)phthalate
245. Complement activation and hypersensitivity reactions to dialysis membranes
246. Eosinophilia and cellular cytokine responsiveness in hemodialysis patients
247. Eosinophilia in chronic dialysis
248. Anaphylactoid reactions in hemodialysis patients treated with the AN69 dialyzer
249. Anaphylactoid reactions during hemodialysis
250. Anaphylactoid reactions during hemodialysis on AN69 membranes in patients receiving ACE inhibitors
251. Bradykinin is a mediator of anaphylactoid reactions during hemodialysis with AN69 membranes
252. Bradykinin generation by dialysis membranes: Possible role in anaphylactic reaction
253. Evaluation of the Losartan in Hemodialysis (ELHE) Study
254. Bradykinin and nitric oxide generation by dialysis membranes can be blunted by alkaline rinsing solutions
255. Use of alkaline rinsing solution to prevent heypersensitivity reactions during hemodialysis: Data from a multicentre retrospective analysis
256. Morphological, biochemical, and functional changes in human platelets subjected to shear stress
257. Alteration of human leukocyte chemotaxis, chemiluminescence, and HMP shunt activity caused by mechanical trauma
258. (A)typical symptoms during single needle dialysis
259. Uremic patients have decreased shear-induced platelet aggregation mediated by decreased availability of glycoprotein IIb-IIIa receptors
260. Red cell injury assessed in a numeric model of a peripheral dialysis needle